Somatuline ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 2 |
| 298 | Hereditary pancreatitis | 1 |
67. Polycystic kidney disease
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-005017-37-NL (EUCTR) | 30/05/2012 | 21/05/2012 | To investigate the effect of Lanreotide on renal function decline in ADPKD patients | A randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study | First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume. MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Somatuline Autogel Product Name: Lanreotide Product Code: BIM 23014 INN or Proposed INN: Lanreotide Other descriptive name: LANREOTIDE ACETATE | DIPAK Consortium | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 2 | EUCTR2009-017849-57-NL (EUCTR) | 24/03/2011 | 13/01/2010 | Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE | Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE | Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease. MedDRA version: 12.1;Level: LLT;Classification code 10048834;Term: Polycystic liver disease MedDRA version: 12.1;Level: PT;Classification code 10036045;Term: Polycystic kidney MedDRA version: 12.1;Classification code 10036046;Term: Polycystic kidney, autosomal dominant MedDRA version: 12.1;Classification code 10036048;Term: Polycystic kidney, unspecified type | Product Name: Sandostatin LAR Product Code: unknown Product Name: Somatuline Autosolution Product Code: unknown | Radboud University Nijmegen Medical Centre | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 4 | Netherlands |
298. Hereditary pancreatitis
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-016082-29-BE (EUCTR) | 10/03/2010 | 25/11/2009 | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Paraduodenal pancreatitis MedDRA version: 12.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis | Trade Name: Somatuline Autogel 90 mg Other descriptive name: LANREOTIDE ACETATE | Erasme hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Belgium |